🇺🇸 FDA
Pipeline program

Novel restraint

18-0353-01

Phase 1 other completed

Quick answer

Novel restraint for Acute Respiratory Failure is a Phase 1 program (other) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).

Program details

Company
Lxo Ireland Designated Activity Company
Indication
Acute Respiratory Failure
Phase
Phase 1
Modality
other
Status
completed

Clinical trials